Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Jiangsu Hengrui Pharmaceutical Co., Ltd. was established in 1970 and is an international pharmaceutical enterprise engaged in innovative and high-quality drug development and promotion. It has developed into a well-known supplier of anti-tumor drugs, surgical drugs, and imaging intervention products in China. In the "2022 Annual Analysis of Pharmaceutical R&D Trends" released by the global pharmaceutical think tank information platform InformaPharmaIntelligence, Hengrui Pharmaceuticals ranks 16th, setting a new high for Chinese pharmaceutical companies on this list; In the 2021 Top 50 Global Pharmaceutical Companies list released by the American Pharmaceutical Managers magazine, Hengrui has been on the list for three consecutive years, ranking 38th year by year; The company has been selected as one of the top 100 pharmaceutical industry enterprises in China for many years, and in 2021, it continued to be the top industrial enterprise in China's pharmaceutical research and development product line. For more than fifty years, Hengrui Pharmaceutical has always been rooted in China, facing the world, focusing on the health industry, focusing on cutting-edge fields, overcoming difficulties, and promoting high-quality development of the pharmaceutical industry. The company regards technological innovation as its primary development strategy. In recent years, the company has continuously invested heavily in research and development. In 2021, the cumulative R&D investment reached 6.203 billion yuan, with R&D investment accounting for 23.95% of operating revenue, ranking at the forefront of the industry. The company has established research and development centers or branches in multiple places in the United States, Europe, Japan, Australia, and China, and has created a global research and development team with over 5400 people in scale, specialization, and comprehensive capabilities. At present, the company has approved 11 innovative drugs for market launch, and more than 60 innovative drugs are currently under clinical development. The company has a rich research and development pipeline, and in addition to traditional advantages in the field of cancer, it also has a forward-looking and extensive layout in multiple treatment fields such as autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, etc. At the same time, a group of new technology platforms with independent intellectual property rights and world-class capabilities have been established, providing a strong foundation for innovative research and development. As of the end of 2021, the company has applied for a total of 1806 invention patents, 494 PCT patents, and has 360 domestic valid authorized invention patents, as well as 478 foreign authorized patents in Europe, America, and Japan. Internationalization is also an important development strategy of Hengrui Pharmaceutical. As of the end of 2021, Hengrui Pharmaceutical products have entered over 40 countries and are continuing to accelerate the development of global markets with a focus on emerging markets. Through cooperation with companies in South Korea and the United States, the company has licensed innovative drugs with independent intellectual property rights such as Karelizumab and SHR0302. At the same time, the company has established a complete clinical research and development team in the United States and Europe, fully launching a global product development team work model, and accelerating the promotion of innovative results to benefit patients worldwide. In addition, the company has obtained more than 20 registration approvals in Europe, America, and Japan, including injections, oral preparations, and inhalation anesthetics, improving the accessibility of drugs to patients in different regions around the world. Perseverance and perseverance lead to success in life. In the future development, Hengrui will continue to adhere to the mission of "technology oriented, creating a healthy life for humanity", with the vision of "focusing on innovation and building a multinational pharmaceutical group", accelerate technological innovation, and strive to develop more new and good drugs to benefit patients and better serve a healthy life!. |
| Headquarter | Lianyungang City |
| Establish Date | 4/28/1997 |
| Listed Code | 600276.SH |
| Listed Date | 10/18/2000 |
| Chairman | Sun Piaoyang. |
| CEO | Dai Hongbin. |
| Website | www.hengrui.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
